Health Professional Radio - Podcast

Returning guest, Dr. Gregg Sylvester, Chief Medical Officer at Seqirus discusses real-world evidence on the company's MF59® Adjuvanted, Trivalent Influenza Vaccine that was recently published in the peer-reviewed medical journal "Vaccine". The study demonstrated that this vaccine was more effective than a standard-dose non-adjuvanted trivalent seasonal vaccine in preventing influenza-related medical office visits and hospitalizations/ER visits in adults 65+ during the 2017/18 U.S. influenza season.